0000950170-24-027509.txt : 20240306
0000950170-24-027509.hdr.sgml : 20240306
20240306201326
ACCESSION NUMBER: 0000950170-24-027509
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240304
FILED AS OF DATE: 20240306
DATE AS OF CHANGE: 20240306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yale Catriona
CENTRAL INDEX KEY: 0001779308
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 24727836
MAIL ADDRESS:
STREET 1: C/O AKERO THERAPEUTICS INC.
STREET 2: 170 HARBOR WAY 3RD FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
ownership.xml
4
X0508
4
2024-03-04
0001744659
Akero Therapeutics, Inc.
AKRO
0001779308
Yale Catriona
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
false
true
false
false
Chief Development Officer
true
Common Stock
2024-03-04
4
M
false
10000
6.36
A
88415
D
Common Stock
2024-03-04
4
M
false
10646
21.09
A
99061
D
Common Stock
2024-03-04
4
S
false
20646
35.49
D
78415
D
Stock Option (Right to Buy)
6.36
2024-03-04
4
M
false
10000
0.00
D
2029-01-15
Common Stock
10000
15172
D
Stock Option (Right to Buy)
21.09
2024-03-04
4
M
false
10646
0.00
D
2029-12-12
Common Stock
10646
74354
D
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 23, 2023, previously adopted by the Reporting Person.
Includes 505 shares acquired under the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan on June 30, 2023.
The options are vested and currently exercisable.
/s/ Jonathan Young, Attorney-in-Fact
2024-03-06